Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4⁺CD25⁺ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor.

ABSTRACT: CD4⁺CD25⁺Foxp3⁺T cell population is heterogenous and contains three major sub-groups. First, thymus derived T regulatory cells (tTreg) that are naïve/resting. Second, activated/memory Treg that are produced by activation of tTreg by antigen and cytokines. Third, effector lineage CD4⁺CD25⁺T cells generated from CD4⁺CD25^- T cells' activation by antigen to transiently express CD25 and Foxp3. We have shown that freshly isolated CD4⁺CD25⁺T cells are activated by specific alloantigen and IL-4, not IL-2, to Ts2 cells that express the IL-5 receptor alpha. Ts2 cells are more potent than naïve/resting tTreg in suppressing specific alloimmunity. Here, we showed rIL-5 promoted further activation of Ts2 c

SUBMITTER: Hall BM 

PROVIDER: S-EPMC8667344 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature